HomeAIM • NYSEAMERICAN
add
AIM ImmunoTech Inc
Previous close
$0.12
Day range
$0.063 - $0.12
Year range
$0.063 - $0.62
Market cap
2.53M USD
Avg Volume
668.43K
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 45.00K | -30.77% |
Operating expense | 5.89M | -58.08% |
Net income | -5.97M | 52.55% |
Net profit margin | -13.26K | 31.46% |
Earnings per share | -0.10 | 64.56% |
EBITDA | -5.79M | 58.48% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 3.98M | -69.57% |
Total assets | 8.61M | -55.59% |
Total liabilities | 9.93M | 8.56% |
Total equity | -1.32M | — |
Shares outstanding | 72.29M | — |
Price to book | -5.89 | — |
Return on assets | -131.89% | — |
Return on capital | -369.07% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -5.97M | 52.55% |
Cash from operations | -3.96M | 59.47% |
Cash from investing | 3.70M | 1,830.84% |
Cash from financing | 1.04M | 605.44% |
Net change in cash | 786.00K | 108.00% |
Free cash flow | -3.65M | 40.05% |
About
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Founded
1966
Headquarters
Website
Employees
22
